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Abstract
The development by the Edmonton group of a sirolimus-based, steroid-free, low-tacrolimus
regimen is a significant breakthrough that allows the rate of insulin independence after islet trans-
plantation to increase from 13% to 80% at 1 year ; however, the rate is reduced to 50% at 3
years, attributed to prolonged tacrolimus exposure. Recently, immunosuppression agents such as
cyclosporine, mycophenolate mofetil, and the novel agent FTY 720 have been used instead of
tacrolimus. Lymphocytedepleting antibodies such as anti-thymocyte globulin, alemtuzumab, and
hOKT3gamma 1 (ala, ala) have been launched, and a costimulatory blockade of anti-CD40 mon-
oclonal antibodies and CTLA4-Ig will be attempted in the near future. Moreover, the potential
of a novel immunosuppressing peptide could now be realized using new technology called the
protein transduction system. In this review, we show some of the most recent contributions to the
advancement of knowledge in this field.
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n 1974,  the ﬁ rst clinical allogeneic islet trans-
plantation was performed at the University of 
Minnesota [1].  Immunosuppressive regimens depend 
heavily on steroids and azathioprine because of the 
previous appearance of calcineurin inhibitors such as 
cyclosporine.  Unfortunately, no patient has achieved 
insulin independence with this procedure,  and only a 
few cases have showed transient graft function,  as 
evidenced by measurable serum C-peptide [1],  and 
even when cyclosporine is available,  there has not 
been much improvement.  In 1988,  Camillo Ricordi 
developed an automated method for the isolation of 
human pancreatic islets [2].  This technique provided 
an opportunity for large numbers of human islets to 
be isolated and transplanted,  leading to the ﬁ rst 
reports of insulin independence using cyclosporine-
based regimens.  [3, 4]
　　Immunosuppressive regimens in the 1990s evolved 
with the release of new compounds, but the rates of 
insulin independence reported by the International 
Islet Transplant Registry (ITR) culminated at a 
disappointing 13ｵ.  At the University of Geneva,  an 
immunosuppression protocol consisted of 
cyclosporine,  azathioprine,  and steroids,  and 
induction therapy was performed for a period of 14 
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days with anti-thymocyte globulin until 1997.  From 
1998 to 2000,  a new protocol consisted of 
cyclosporine,  mycophenolate mofetil,  and steroids, 
and induction therapy with basiliximab was 
performed on day 0 and 4.  This is the ﬁ rst report of 
the use of an anti-interleukin-2-receptor monoclonal 
antibody in islet transplantation [5,  6].  The protocol 
was used in the initial experience of the Swiss-
French GRAGIL consortium from 1999 to 2000.  At 
the completion of a 12-month follow up,  0ｵ primary 
nonfunction,  50ｵ graft survival, and 20ｵ insulin 
independence were observed [7].  The Giessen group 
reported remarkable results in the late 1990s,  with 
approximately 30ｵ of transplanted patients 
achieving insulin independence [8,  9].  The Milan 
group has reported that 35ｵ of 20 consecutive 
patients receiving islets after kidney grafts achieved 
insulin independence [10].  Remarkably,  the Giessen 
and Milan results were achieved with a conventional 
immunosuppressive regimen including steroids and 
cyclosporine,  which has been preferred over 
tacrolimus because of its alleged lower islet toxicity.
　　In 2000,  the Edmonton group reported extremely 
impressive advances in clinical islet transplanta-
tion.  All 7 consecutive recipients of allogeneic islet 
grafts achieved insulin independence [11].  A 
subsequent update of their results reported an 80ｵ 
actual rate of insulin independence at 1 year [12, 
13].  This observation has led to renewed interest in 
islet of Langerhans transplantation as a means of 
curing diabetes, as clinical programs are being 
started at an increasing number of transplant centers 
throughout the world.  The design of a sirolimus-
based,  steroid-free,  low-tacrolimus regimen has 
fundamental to this progress.
　　Currently explored alternatives to tacrolimus 
include cyclosporine,  mycophenolate mofetil,  and the 
novel agent FTY 720 [14, 15].  To achieve tolerance, 
several strategies using lymphocyte-depleting 
antibodies (anti-thymocyte globulin,  alemtuzumab, 
hOKT3ｺ1 (ala,  ala)),  or costimulatory blockade 
(anti-CD40 antibody,  CTLA4-Ig) have been 
performed [16-19].  Moreover,  the potential of a 
novel immunosuppressing peptide could now be 
realized,  thanks to a new cell-delivery system 
[20].  Here, we review some of the most recent 
contributions to the advancement of knowledge in this 
ﬁ eld.
Immunosuppressant of the Edmonton
protocol
　　The Edmonton protocol uniquely combines several 
strategies designed to speciﬁ cally address the vari-
ous obstacles encountered in the isolation,  transplan-
tation,  and immunosuppression sequence.  One of 
these strategies involves an improved immunosup-
pressive protocol consisting of sirolimus 
(rapamycin),  low-dose tacrolimus, and anti-IL2-
receptor monoclonal antibody (daclizumab) 
induction.  The immunosuppressive protocol avoids 
the diabetrogenic eﬀ ects of glucocorticoids in islet 
transplantation.  Although the mechanisms are not 
fully understood,  the existence of glucocorticoid-
induced hyperglycemia has long been acknowledged, 
and its detrimental eﬀ ects on islet function in vitro 
and in vivo have been described [21, 22].
　　Calcineurin inhibitors such as tacrolimus have 
also been associated with impaired in vitro and in vivo 
islet graft function [22,  23].  Moreover,  long-term 
studies have shown that short-term cyclosporine in 
dogs can result in the permanent loss of functionally 
competent islets [24].  A study of biopsies obtained 
from whole pancreas transplants in hosts treated 
with cyclosporine or tacrolimus resulted in observa-
tion of cytoplasmic swelling,  vacuolization,  and 
apoptosis as evidence of direct islet cell damage. 
The presence and extent of damage appears to corre-
late with high serum levels of calcineurin inhibitors 
and pulse steroid administration.  The lesions are 
also more marked with tacrolimus than with cyclospo-
rine therapy [25].   These observations provide a 
rationale for a glucocorticoid-free regime and for 
lowering the dosages of calcineurin inhibitors in the 
Edomonton immunosuppressive protocol.
　　Sirolimus has been shown to be a rather harmless 
agent in terms of islet toxicity.  In vitro impairment of 
islet function is seen only at extremely high sirolimus 
concentrations.  At doses 10 to 50 times the eﬀ ective 
antirejection dosage,  hyperglycemia has been 
observed in islet-transplanted animals without histo-
logical evidence of end-organ toxicity [26].  The syn-
ergism of sirolimus and calcineurin inhibitors allows 
their dosage to be reduced substantially,  and thus 
islet toxicity,  without increasing the occurrence of 
acute rejection episodes [27,  28].  Since both siroli-
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mus and tacrolimus bind to FKBP-12,  competition 
for FKBP-12 would prevent synergism [29] ;  how-
ever,  in vivo observations in both animal models and 
humans suggest a strong potentiation of the eﬃ  cacy 
of both drugs [30-32].
　　It appears that the actual rate of insulin indepen-
dence is 80ｵ at 1 year and 50ｵ at 3 years in 
Edmonton patients.  The reasons for the decrease in 
islet function after the ﬁ rst year are not well under-
stood.  Although the dose of tacrolimus is low,  the 
long-term toxicity of tacrolimus to islets has been 
suspected.  In addition to tacrolimus toxicity,  rela-
tively high doses of sirolimus (trough levels of 10-15 
ng/mL for the ﬁ rst 3 months) have been associated 
with serious side eﬀ ects.  The most notable reported 
side eﬀ ects of sirolimus are mouth ulcerations,  dys-
lipidemia,  and myelotoxicity.  It is a matter of con-
cern that such side eﬀ ects are experienced by almost 
all patients.
Progressive immunosuppressive protocol and 
perspectives for the near future
　　After the Edmonton protocol report,  several 
institutions have considered calcineurin inhibitor-free 
regimens to be an excellent way of avoiding drug-
induced diabetogenicity and of minimizing the devel-
opment of kidney toxicity in patients prone to devel-
oping diabetic nephropathy.  The Minneapolis group 
has shown excellent results using tacrolimus as the 
initial immunosuppression,  followed by the gradual 
replacement of tacrolimus with mycophenolate mofetil 
as maintenance immunosuppression beginning 1-month 
posttransplant [14].  The same group has also shown 
preliminary evidence of the safety and eﬃ  cacy of cor-
ticosteroid and calcineurin inhibitor-free immunosup-
pression in a relevant preclinical transplant model 
[15].  Induction immunosuppression was carried out 
in this previous study with intravenous basiliximab, 
anti-IL-2 receptor blockade,  which has been used in 
clinical islet transplantation from non-heart beating 
and living donors in our university instead of dacli-
zumab [33,  34].  Maintenance immunosuppression 
was with everolimus, sirolimus analogue,  and FTY 
720.  FTY 720 is a novel immunosuppressive agent 
that acts on lymphocyte homing and thus interferes 
with T cell-antigen cognate interaction.  The avail-
ability of FTY 720 for phase II clinical trials of islet 
transplantation is eagerly anticipated.
　　The use of lymphocyte-depleting agents during the 
induction period has been attempted with success in 
protocols based on tacrolimus-sirolimus association 
by the Minneapolis group.  The use of anti-thymocyte 
globulin and the humanized anti-CD3 monoclonal anti-
body (mAb) hOKT3ｺ1 (ala-ala),  lacking Fc-receptor-
binding properties (and thus avoiding massive cyto-
kine release by cross-linked macrophages) and with 
reduced immunogenicity, has resulted in high rates of 
insulin independence after single donor islet trans-
plantation [16].  The Edmonton group is currently 
testing humanized mAb alemtuzumab (Campath-1H) in 
a group of islet transplant recipients.  This compound 
targets the CD52 molecule, located on the cell sur-
face of lymphocytes and monocytes,  resulting in last-
ing and profound depletion of these lineages.  Results 
equivalent to those obtained with the original 
Edmonton protocol have been reported [35].
　　Biological agents that block key T cell costimula-
tory signals have demonstrated extraordinary prom-
ise in animal models.  Both CD28 and CD154 mole-
cules are located at the surface of CD4(+) T cells 
and deliver costimulatory signals.  Two types of 
costimulatory blocking agents,  CTLA4-Ig preventing 
CD28-CD80/86 interaction and anti-CD154 prevent-
ing CD40-CD154 interaction,  have reached the pre-
clinical stage.  In a nonhuman primate model, 
LEA29Y,  a mutant CTLA4-Ig molecule with 
increased binding activity,  sirolimus,  and the anti-
IL-2R regimen have signiﬁ cantly prolonged islet 
allograft survival [17].  Islet transplantation under 
the cover of anti-CD154 monotherapy consistently 
allows for allogeneic islet engraftment and long-term 
insulin independence in this highly relevant preclini-
cal model [19].  From these studies,  the concept of 
maintenance therapy with costimulatory blocking 
agents has emerged as a valid strategy for clinical 
islet transplantation.  A clinical trial utilizing human-
ized anti-CD154 mAb in recipients of solitary islet 
transplants commenced in 1999 ; however,  it was 
reported that unusual thromboembolic complications 
occurred in kidney transplant recipients receiving 
mAb in a concurrent trial [36, 37].  To circumvent 
this potential complication,  an Emory University 
group developed a chimeric antibody targeting CD40 
as an alternative to CD154.  Anti-CD40 combined 
with LEA29Y dramatically facilitates long-term islet 
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allograft survival [18].
Development of immunosuppressive agents by 
protein transduction technology
　　An important mechanism whereby calcineurin pro-
motes T cell activation and cytokine gene induction is 
largely attributed to a family of transcriptional regu-
lators referred to as the nuclear factor of activated 
T cells (NFAT).  Immunosuppressants cyclosporine 
A and FK506 inhibit the activity of calcineurin phos-
phatase on all its protein substrates,  including 
NFAT [38, 39].  These drugs have revolutionized 
transplant therapy ; however,  the inhibition of calci-
neurin outside the immune system has a number of 
side eﬀ ects including hyperglycemia,  progressive 
loss of renal function, hypertension,  neurotoxicity, 
and increased risk of malignancy [40-43].  In partic-
ular, the use of FK506 and cyclosporine A in human 
organ transplantation has been associated with a 
10-30ｵ incidence of diabetes [44].
　　In the search for safer drugs,  we have developed 
a cell-permeable inhibitor of NFAT using the protein 
transduction system [20, 45-52].  The NFAT inhibi-
tor peptide, VIVIT,  was has been developed based 
on the conserved calcineurin docking site of the 
NFAT family [53].  The peptide interferes selec-
tively with calcineurin-NFAT interactions without 
affecting any of calcineurin’s other targets. 
Therefore,  VIVIT might be useful as a therapeutic 
agent that is less toxic than current drugs.  The 
NFAT inhibitory peptide was covalently linked at its 
C terminus to a short stretch of arginine residues 
(11R-VIVIT).  Polyarginine facilitates the uptake of 
peptides and protein into cells with high eﬃ  ciency 
[20, 46-50].  This peptide has been observed to spe-
ciﬁ cally and signiﬁ cantly inhibited NFAT function in 
a T cell line,  and appears stable enough to survive in 
the circulation of a mouse model.  Using a mouse 
model of diabetes,  we investigated whether 
11R-VIVIT can prevent transplant rejection. 
Following the transplantation of islet cells from fully 
mismatched mice, treatment with the peptide was 
observed to prolong graft survival,  and the trans-
planted islet cells were still producing insulin 50 
days later.  Moreover,  insulin secretion did not 
change at any concentration of 11R-VIVIT,  whereas 
FK506 inhibited insulin secretion,  and the amount 
secreted decreased signiﬁ cantly.  These results indi-
cate that the NFAT inhibitor peptide is less toxic 
than calcineurin inhibitors with regard to insulin 
secretion [20].
　　Although the peptide is a long way from clinical 
trials,  the above strategy provides interesting proof 
that the toxicity of calcineurin inhibitors can be 
reduced.
Conclusions
　　Immunosuppression is critical in islet transplanta-
tion because islet grafts are prone to immune 
destruction not only by allorejection,  but also by the 
recurrence of autoimmunity.  New agents other than 
calcineurin inhibitors should be developed with the 
aim of solving diabetogenicity and nephrotoxicity 
problems.  The next step should probably be the 
development of new agents other than sirolimus to 
avoid the problematic side eﬀ ects of the drug.  Safer 
immune suppressors will have beneﬁ ts not only for 
transplant patients.  If there are fewer side eﬀ ects, 
the drugs could then be employed in treating autoim-
mune diseases such as psoriasis, for which current 
drugs are considered too dangerous.
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